Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer

BRCA1/2-deficient ovarian carcinoma (OC) has been shown to be particularly sensitive to poly (ADP-ribose) polymerase inhibitors (PARPis). Furthermore, BRCA1/2 mutation status is currently used as a predictive biomarker for PARPi therapy. Despite providing a major clinical benefit to the majority of...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Ou, Dash, Sweta, Nepomuceno, Thales C., Fang, Bin, Yun, Sang Y., Welsh, Eric A., Lawrence, Harshani R., Marchion, Douglas, Koomen, John M., Monteiro, Alvaro N., Rix, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636579/
https://www.ncbi.nlm.nih.gov/pubmed/36183837
http://dx.doi.org/10.1016/j.jbc.2022.102550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636579/
https://www.ncbi.nlm.nih.gov/pubmed/36183837
http://dx.doi.org/10.1016/j.jbc.2022.102550

Ejemplares similares